- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Impact of Friedreich Ataxia on Quality of Life
Sub Subramony, M.D., discusses how the progression of patients' conditions often leads to a decline in quality of life and functional capabilities, highlighting key clinical indicators that necessitate the adoption of mobility aids.
EP: 1.Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities
EP: 2.Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
EP: 3.Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
EP: 4.Managing Adverse Events in Novel Friedreich’s Ataxia Therapy
EP: 5.Examining Trial Data on Omaveloxolone Efficacy
EP: 6.Promising Therapy Approaches for Advanced Friedreich Ataxia
EP: 7.Friedreich Ataxia: Looking Forward at the Treatment Landscape
EP: 8.Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia
EP: 9.Diagnosis of Friedreich Ataxia
EP: 10.Impact of Friedreich Ataxia on Quality of Life
EP: 11.Clinical Utility of the Modified Friedreich Ataxia Rating Scale
EP: 12.Comorbidities and Complications Associated With Friedreich Ataxia
EP: 13.Challenges Associated With Friedreich Ataxia
EP: 14.Future Considerations for Friedreich Ataxia
Video content above is prompted by the following:
Can you shed light on the trajectory of patients’ quality of life, functional capabilities, and overall well-being as the condition advances, and how do you typically discern indications in clinical settings that signal a decline in ambulation necessitating the adoption of mobility aids?
Alzheimer Disease and Related Dementias Cause Surging Economic Burden for Minoritized Communities
June 5th 2025African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.
Read More
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
